Classification of current anticancer immunotherapies Journal Article
| Authors: | Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J. M.; Buqué, A.; Senovilla, L.; Baracco, E. E.; Bloy, N.; Castoldi, F.; Abastado, J. P.; Agostinis, P.; Apte, R. N.; Aranda, F.; Ayyoub, M.; Beckhove, P.; Blay, J. Y.; Bracci, L.; Caignard, A.; Castelli, C.; Cavallo, F.; Celis, E.; Cerundolo, V.; Clayton, A.; Colombo, M. P.; Coussens, L.; Dhodapkar, M. V.; Eggermont, A. M.; Fearon, D. T.; Fridman, W. H.; Fucíková, J.; Gabrilovich, D. I.; Galon, J.; Garg, A.; Ghiringhelli, F.; Giaccone, G.; Gilboa, E.; Gnjatic, S.; Hoos, A.; Hosmalin, A.; Jäger, D.; Kalinski, P.; Kärre, K.; Kepp, O.; Kiessling, R.; Kirkwood, J. M.; Klein, E.; Knuth, A.; Lewis, C. E.; Liblau, R.; Lotze, M. T.; Lugli, E.; Mach, J. P.; Mattei, F.; Mavilio, D.; Melero, I.; Melief, C. J.; Mittendorf, E. A.; Moretta, L.; Odunsi, A.; Okada, H.; Palucka, A. K.; Peter, M. E.; Pienta, K. J.; Porgador, A.; Prendergast, G. C.; Rabinovich, G. A.; Restifo, N. P.; Rizvi, N.; Sautès-Fridman, C.; Schreiber, H.; Seliger, B.; Shiku, H.; Silva-Santos, B.; Smyth, M. J.; Speiser, D. E.; Spisek, R.; Srivastava, P. K.; Talmadge, J. E.; Tartour, E.; Van Der Burg, S. H.; van den Eynde, B. J.; Vile, R.; Wagner, H.; Weber, J. S.; Whiteside, T. L.; Wolchok, J. D.; Zitvogel, L.; Zou, W.; Kroemer, G. |
| Article Title: | Classification of current anticancer immunotherapies |
| Abstract: | During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches. |
| Keywords: | osteosarcoma; unclassified drug; acute granulocytic leukemia; doxorubicin; drug efficacy; nonhuman; solid tumor; alpha2b interferon; bcg vaccine; interleukin 2; ipilimumab; unindexed drug; cancer immunotherapy; melanoma; bortezomib; mantle cell lymphoma; multiple myeloma; imiquimod; actinic keratosis; basal cell carcinoma; dendritic cell; granulocyte macrophage colony stimulating factor; cyclophosphamide; hematopoietic stem cell transplantation; chronic myeloid leukemia; kidney carcinoma; monoclonal antibody; colorectal carcinoma; hematologic malignancy; head and neck cancer; breast carcinoma; cancer immunization; mitoxantrone; oncolytic virus; oncolytic viruses; bleomycin; epirubicin; lung carcinoma; dna vaccine; thyroid carcinoma; immunostimulation; alpha2a interferon; peptide vaccine; vitespen; oxaliplatin; chronic lymphatic leukemia; transitional cell carcinoma; stomach carcinoma; antigen presenting cell; alemtuzumab; dna immunization; cell transfer; uterine cervix carcinoma; mifamurtide; prostate carcinoma; hairy cell leukemia; metastatic melanoma; adoptive cell transfer; wart virus vaccine; indoleamine 2,3 dioxygenase inhibitor; active immunization; passive immunization; condyloma acuminatum; sipuleucel t; phosphoryl lipid a; nivolumab; human; article; pembrolizumab; checkpoint blockers; dendritic cell-based interventions; dna-based vaccines; immunostimulatory cytokines; peptide-based vaccines; toll-like receptor agonists; oncorine; picibanil |
| Journal Title: | Oncotarget |
| Volume: | 5 |
| Issue: | 24 |
| ISSN: | 1949-2553 |
| Publisher: | Impact Journals |
| Date Published: | 2014-12-30 |
| Start Page: | 12472 |
| End Page: | 12508 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 25537519 |
| PMCID: | PMC4350348 |
| DOI: | 10.18632/oncotarget.2998 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work